The purposes of this study are:

• To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and
• To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.

Inclusion Criteria:

• Healthy male or female subjects of non-childbearing potential

Exclusion Criteria:

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).